A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers

A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers

OBJECTIVES: The duration of life of patients with schizophrenia is shorter than that of the general population for various reasons. Especially cardiovascular diseases are one of the most important causes of death in patients with schizophrenia. Our aim in this study is comparison of second-generatio...

Full description

Bibliographic Details
Main Authors:	Demet Sağlam Aykut, Evrim Özkorumak Karagüzel
Format:	Article
Language:	English
Published:	AVES 2018-07-01
Series:	Psychiatry and Clinical Psychopharmacology
Subjects:	Schizophrenia metabolic sydrome second-generation antipsychotics oral antipsychotics depot antipsychotics adverse effect
Online Access:	http://dx.doi.org/10.1080/24750573.2017.1414575

Similar Items

A cross sectional study of trihexyphenidyl utilization on patient receiving antipsychotic therapy
by: Addiniya Nurul Azmi, et al.
Published: (2016-06-01)

Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update
by: Balázs, T., et al.
Published: (2022)

Antipsicóticos de ação prolongada no tratamento de manutenção da esquizofrenia: Parte I. Fundamentos do seu desenvolvimento, benefícios e nível de aceitação em diferentes países e culturas
by: Luiz Paulo de C. Bechelli

Antipsychotic use in a resource-limited setting: Findings in an Eastern Cape psychiatric hospital
by: Ingrid Eloff, et al.
Published: (2017-07-01)

Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients’ and clinicians’ perspectives after a 12-month randomized controlled trial
by: Ernst L. Noordraven, et al.
Published: (2017-08-01)

Pharmacoeconomic comparison of ziprasidone with other atypical oral antipsychotic agents in schizophrenia
by: Andrea Fagiolini, et al.
Published: (2011-11-01)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

Clinical use of second-generation antipsychotics in children
by: Kirsi Kakko, et al.
Published: (2017-10-01)

The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population
by: Osama Abo Alrob, et al.
Published: (2019-06-01)

THE ROLE OF ATYPICAL ANTIPSYCHOTIC DECREASING AGGRESIVENESS IN SCHIZOPHRENIA
by: Juvita Novia Anggraini Maria
Published: (2013-03-01)

Quo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context
by: Francisco López-Muñoz, et al.
Published: (2015-09-01)

Second generation antipsychotics causing neuroleptic malignant syndrome
by: C. Suraweera, et al.
Published: (2016-12-01)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Anderson, M., et al.
Published: (2021)

Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications
by: M S Karthik, et al.
Published: (2014-01-01)

Atypical Antipsychotics Induced Metabolic Syndrome
by: Aysegul Demirel, et al.
Published: (2015-03-01)

К вопросу о комбинированной терапии шизофрении Н.Н. Петрова
by: Петрова, Н.Н.
Published: (2020-04-01)

The effects of antipsychotic medications on microbiome and weight gain in children and adolescents
by: Tali Bretler, et al.
Published: (2019-06-01)

Atypical antipsychotics as add-on treatment in late-life depression
by: Cakir S, et al.
Published: (2016-09-01)

Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
by: Sebastiano Alfio Torrisi, et al.
Published: (2020-11-01)

Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?
by: Francky Teddy Endomba, et al.
Published: (2020-02-01)

Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
by: Xu H, et al.
Published: (2019-07-01)

Models of treatment with antipsychotics of the schizophrenic patients
by: Svjetlana Loga-Zec, et al.
Published: (2005-11-01)

The influence of typical and atypical antipsychotics on neurocognitive functions in patients with psychotic disorders
by: Javorac Jovan M., et al.
Published: (2019-01-01)

Differences in the Effectiveness of Long-Acting Injection and Orally Administered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services
by: Hsiao-Fen Hsu, et al.
Published: (2019-06-01)

Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile
by: Zolezzi M, et al.
Published: (2021-06-01)

Comparison of Prescribing Patterns for Typical and Atypical Antipsychotics in Patients with Schizophrenia Before and After the Publication of the Phase I "CATIE" Trial
by: Varga, Ross
Published: (2007)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
by: Leonid Mikhaylovich Bardenshteyn, et al.
Published: (2010-06-01)

Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia
by: Barteček Richard, et al.
Published: (2011-10-01)

Sex Selection Bias in Schizophrenia Antipsychotic Trials—An Update Systematic Review
by: Lais Fonseca, et al.
Published: (2021-05-01)

Atypical antipsychotics for delirium in hospitalized patients
by: Daniza Belén Bilicic Ubierna, et al.
Published: (2021-05-01)

Antipsychotic treatments; Focus on lurasidone
by: Tomiki eSumiyoshi
Published: (2013-08-01)

Evaluation of long acting, oral and combination antipsychotic treatments in patients with psychotic disorder (tur)
by: Yasir Şafak, et al.
Published: (2020-01-01)

Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand
by: Boonlue T, et al.
Published: (2016-04-01)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
by: Fang X, et al.
Published: (2019-07-01)

Problems with the Administration of Antipsychotic Drugs in Depot Formulations in the Treatment of Schizophrenia
by: Ranković Anica, et al.
Published: (2018-03-01)

Effect of atypical antipsychotic on blood pressure in inpatients with schizophrenia of Prof. Dr. Soerojo Mental Health Hospital Magelang
by: Haafizah Dania, et al.
Published: (2019-01-01)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
by: Eiji Kirino
Published: (2017-11-01)

A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia
by: Amrita Prakash Singam, et al.
Published: (2011-01-01)

Association of metabolic syndrome with schizophrenia
by: Sarita Bajaj, et al.
Published: (2013-01-01)